ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage
ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is giving an update on the use of the “at-the market” equity of its providing program.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement a “at the market” equity offering program under which Acasti might issue as well as sell from time to time its everyday shares having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January twenty seven, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares ended up being sold at prevailing market costs averaging US$1.0747 per share. No securities had been offered throughout the facilities of the TSXV or perhaps, to the understanding of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with their services. As a result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and can supply the Company with more freedom in its continuous review process to explore as well as evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescription medications making use of OM3 greasy acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical proof of efficacy as well as safety in lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of this press release which aren’t statements of historical or current truth constitute “forward looking information” within the meaning of Canadian securities laws and “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking statements include known and unknown risks, uncertainties, and other unknown elements that can result in the particular outcomes of Acasti to be materially different from historical outcomes and even from any later results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, people are actually urged to look at statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward looking statements, which speak only as of the day of this particular press release. Forward-looking claims in that press release include, but are not restricted to, statements or info concerning Acasti’s strategy, future operations and the review of its of strategic options.
The forward looking statements contained in this specific press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward Looking Statements” section found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor section of Acasti’s website at www.acastipharma.com. Many forward-looking claims in that press release are available as of the particular date of this press release.
ACST Stock – Acasti doesn’t undertake to redesign any such forward-looking statements whether as a result of info which is new, future events or otherwise, except as called for by law. The forward-looking claims contained herein are also subject typically to risks and assumptions as well as uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage
